Heron L, Virsolvy A, Peyrollier K, Gribble F M, Le Cam A, Ashcroft F M, Bataille D
Institut National de la Santé et de la Recherche Médicale U 376, CHU Arnaud-de-Villeneuve, 371 Avenue du Doyen Gaston Giraud, 34295 Montpellier Cedex 05, France.
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8387-91. doi: 10.1073/pnas.95.14.8387.
Sulfonylureas are a class of drugs commonly used in the management of non-insulin-dependent diabetes mellitus. Their therapeutic action results primarily from their ability to inhibit ATP-sensitive potassium (KATP) channels in the plasma membrane of pancreatic beta cells and thereby stimulate insulin release. A key question is whether an endogenous ligand for the KATP channel exists that is able to mimic the inhibitory effects of sulfonylureas. We describe here the cloning of the cDNA encoding human alpha-endosulfine, a 13-kDa peptide that is a putative candidate for such a role. alpha-Endosulfine is expressed in a wide range of tissues including muscle, brain, and endocrine tissues. The recombinant protein displaces binding of the sulfonylurea [3H]glibenclamide to beta cell membranes, inhibits cloned KATP channel currents, and stimulates insulin secretion. We propose that endosulfine is an endogenous regulator of the KATP channel, which has a key role in the control of insulin release and, more generally, couples cell metabolism to electrical activity.
磺脲类药物是一类常用于治疗非胰岛素依赖型糖尿病的药物。它们的治疗作用主要源于其抑制胰腺β细胞膜上ATP敏感性钾(KATP)通道的能力,从而刺激胰岛素释放。一个关键问题是是否存在一种KATP通道的内源性配体,能够模拟磺脲类药物的抑制作用。我们在此描述了编码人α-内磺素的cDNA的克隆,α-内磺素是一种13 kDa的肽,可能是发挥这种作用的候选物质。α-内磺素在包括肌肉、脑和内分泌组织在内的多种组织中表达。重组蛋白可取代磺脲类药物[3H]格列本脲与β细胞膜的结合,抑制克隆的KATP通道电流,并刺激胰岛素分泌。我们认为内磺素是KATP通道的内源性调节剂,在胰岛素释放的控制中起关键作用,更普遍地说,它将细胞代谢与电活动联系起来。